Marissa Shrader, Ph.D.
Affiliations: | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Oncology, Cell BiologyGoogle:
"Marissa Shrader"Parents
Sign in to add mentor| David J. McConkey | grad student | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston | |
| (Tumor heterogeneity dictates sensitivity to gefitinib (Iressa(TM)/ZD1839) in solid tumor models.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Metwalli AR, Khanbolooki S, Jinesh G, et al. (2010) Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biology & Therapy. 10: 885-92 |
| Pino MS, Shrader M, Baker CH, et al. (2010) Correction: Transforming growth factor α expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines (Cancer Research (2006) 66, 7, (3802-3812)) Cancer Research. 70: 852-853 |
| Black PC, Brown GA, Inamoto T, et al. (2008) Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1478-86 |
| Shrader M, Pino MS, Lashinger L, et al. (2007) Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Research. 67: 1430-5 |
| Shrader M, Pino MS, Brown G, et al. (2007) Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Molecular Cancer Therapeutics. 6: 277-85 |
| Pino MS, Shrader M, Baker CH, et al. (2006) Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Research. 66: 3802-12 |
| McConkey D, Shrader M, Pino M, et al. (2006) 478 POSTER Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated XIAP expression European Journal of Cancer Supplements. 4: 146 |
| Lashinger LM, Zhu K, Williams SA, et al. (2005) Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Research. 65: 4902-8 |
| Bruns CJ, Shrader M, Harbison MT, et al. (2002) Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. International Journal of Cancer. Journal International Du Cancer. 102: 101-8 |